{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:19:03Z","timestamp":1792873143952,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stefan-Morsch-Stiftung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients supplemented by WES and RNA-seq as well as ATAC-seq on selected cases. We determined the BPDCN DNA methylation profile and observed a dramatic loss of DNA methylation during malignant transformation from early and mature DCs towards BPDCN. DNA methylation profiles further differentiate between BPDCN, AML, CMML, and T-ALL exhibiting the most striking global demethylation, mitotic stress, and merely localized DNA hypermethylation in BPDCN resulting in pronounced inactivation of tumor suppressor genes by comparison. DNA methylation-based analysis of the tumor microenvironment by MethylCIBERSORT yielded two, prognostically relevant clusters (IC1 and IC2) with specific cellular composition and mutational spectra. Further, the transcriptional subgroups of BPDCN (C1 and C2) differ by DNA methylation signatures in interleukin\/inflammatory signaling genes but also by higher transcription factor activity of JAK-STAT and NFkB signaling in C2 in contrast to an EZH2 dependence in C1-BPDCN. Our integrative characterization of BPDCN offers novel molecular insights and potential diagnostic applications.<\/jats:p>","DOI":"10.1038\/s41375-024-02240-8","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:02:00Z","timestamp":1712728920000},"page":"1086-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features"],"prefix":"10.1038","volume":"38","author":[{"given":"Axel","family":"K\u00fcnstner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-7125","authenticated-orcid":false,"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"St\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lohneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Janke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maede","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-2839","authenticated-orcid":false,"given":"Xingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"S\u00fcltmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9231-9291","authenticated-orcid":false,"given":"Emil","family":"Chteinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-2544","authenticated-orcid":false,"given":"Anja","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-3703","authenticated-orcid":false,"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-4521","authenticated-orcid":false,"given":"Hauke","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred C.","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0566-4554","authenticated-orcid":false,"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2240_CR1","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","volume":"97","author":"L Chaperot","year":"2001","unstructured":"Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210\u20137.","journal-title":"Blood"},{"key":"2240_CR2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2240_CR3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2240_CR4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","volume":"5","author":"F Renosi","year":"2021","unstructured":"Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, et al. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv. 2021;5:1540\u201351.","journal-title":"Blood Adv"},{"key":"2240_CR5","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1093\/bioinformatics\/btx502","volume":"33","author":"P Carmona-Saez","year":"2017","unstructured":"Carmona-Saez P, Varela N, Luque MJ, Toro-Dominguez D, Martorell-Marugan J, Alarcon-Riquelme ME, et al. Metagene projection characterizes GEN2.2 and CAL-1 as relevant human plasmacytoid dendritic cell models. Bioinformatics. 2017;33:3691\u20135.","journal-title":"Bioinformatics"},{"key":"2240_CR6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00699-1","volume":"12","author":"A K\u00fcnstner","year":"2022","unstructured":"K\u00fcnstner A, Schwarting J, Witte HM, Bernard V, St\u00f6lting S, Kusch K, et al. Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. Blood Cancer J. 2022;12:101.","journal-title":"Blood Cancer J"},{"key":"2240_CR7","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4:4838\u201348.","journal-title":"Blood Adv"},{"key":"2240_CR8","doi-asserted-by":"crossref","unstructured":"Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2022;12:522\u201341.","DOI":"10.1158\/2159-8290.CD-20-1513"},{"key":"2240_CR9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137:1377\u201391.","journal-title":"Blood"},{"key":"2240_CR10","doi-asserted-by":"crossref","unstructured":"Zalmai L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, et al. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica. 2021;106:3056\u201366.","DOI":"10.3324\/haematol.2020.253740"},{"key":"2240_CR11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/modpathol.2013.238","volume":"27","author":"NA Sangle","year":"2014","unstructured":"Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, et al. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol. 2014;27:1137\u201343.","journal-title":"Mod Pathol"},{"key":"2240_CR12","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","volume":"3","author":"F Garnache-Ottou","year":"2019","unstructured":"Garnache-Ottou F, Vidal C, Biichle S, Renosi F, Poret E, Pagadoy M, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3:4238\u201351.","journal-title":"Blood Adv"},{"key":"2240_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440\u20136.","journal-title":"Blood"},{"key":"2240_CR14","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559\u201362.","journal-title":"Blood"},{"key":"2240_CR15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N. Engl J Med. 2019;380:1628\u201337.","journal-title":"N. Engl J Med"},{"key":"2240_CR16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469\u201374.","journal-title":"Nature"},{"key":"2240_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20603-4","volume":"12","author":"C Koelsche","year":"2021","unstructured":"Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12:498.","journal-title":"Nat Commun"},{"key":"2240_CR18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2240_CR19","doi-asserted-by":"crossref","first-page":"2723.","DOI":"10.1182\/blood-2019-132185","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Kantarjian HM, Khoury JD, Loghavi S, O\u2019Brien S, Cortes JE. et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly presents in the setting of prior or concomitant hematologic malignancies (PCHM): patient characteristics and outcomes in the rapidly evolving modern targeted therapy era. Blood. 2019;134:2723.","journal-title":"Blood"},{"key":"2240_CR20","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","volume":"35","author":"K Batta","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. 2021;35:3299\u2013303.","journal-title":"Leukemia"},{"key":"2240_CR21","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/leu.2017.38","volume":"31","author":"L Brunetti","year":"2017","unstructured":"Brunetti L, Di Battista V, Venanzi A, Schiavoni G, Martelli MP, Ascani S, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238\u201340.","journal-title":"Leukemia"},{"key":"2240_CR22","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Furness A, Joshi K, Ghorani E, Ford K, Ward MJ, et al. Pan-cancer deconvolution of tumour composition using DNA methylation. Nat Commun. 2018;9:3220.","journal-title":"Nat Commun"},{"key":"2240_CR23","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1158\/1078-0432.CCR-22-0391","volume":"28","author":"K Guidry","year":"2022","unstructured":"Guidry K, Vasudevaraja V, Labbe K, Mohamed H, Serrano J, Guidry BW, et al. DNA methylation profiling identifies subgroups of lung adenocarcinoma with distinct immune cell composition, DNA methylation age, and clinical outcome. Clin Cancer Res. 2022;28:3824\u201335.","journal-title":"Clin Cancer Res"},{"key":"2240_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1066-1","volume":"17","author":"R Pidsley","year":"2016","unstructured":"Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208.","journal-title":"Genome Biol"},{"key":"2240_CR25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1101\/gr.275269.121","volume":"32","author":"H Zhang","year":"2022","unstructured":"Zhang H, Polavarapu VK, Xing P, Zhao M, Mathot L, Zhao L, et al. Profiling chromatin accessibility in formalin-fixed paraffin-embedded samples. Genome Res. 2022;32:150\u201361.","journal-title":"Genome Res"},{"key":"2240_CR26","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.immuni.2021.10.001","volume":"54","author":"R Roy","year":"2021","unstructured":"Roy R, Ramamoorthy S, Shapiro BD, Kaileh M, Hernandez D, Sarantopoulou D, et al. DNA methylation signatures reveal that distinct combinations of transcription factors specify human immune cell epigenetic identity. Immunity. 2021;54:2465\u201380.e2465.","journal-title":"Immunity"},{"key":"2240_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-8935-7-21","volume":"7","author":"X Zhang","year":"2014","unstructured":"Zhang X, Ulm A, Somineni HK, Oh S, Weirauch MT, Zhang HX, et al. DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells. Epigenetics Chromatin. 2014;7:21.","journal-title":"Epigenetics Chromatin"},{"key":"2240_CR28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2240_CR29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/15592294.2017.1405199","volume":"13","author":"L Palomo","year":"2018","unstructured":"Palomo L, Malinverni R, Cabezon M, Xicoy B, Arnan M, Coll R, et al. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics. 2018;13:8\u201318.","journal-title":"Epigenetics"},{"key":"2240_CR30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"2240_CR31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","volume":"618","author":"GK Griffin","year":"2023","unstructured":"Griffin GK, Booth CAG, Togami K, Chung SS, Ssozi D, Verga JA, et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023;618:834\u201341.","journal-title":"Nature"},{"key":"2240_CR32","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s43018-020-00131-2","volume":"1","author":"M Duran-Ferrer","year":"2020","unstructured":"Duran-Ferrer M, Clot G, Nadeu F, Beekman R, Baumann T, Nordlund J, et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nat Cancer. 2020;1:1066\u201381.","journal-title":"Nat Cancer"},{"key":"2240_CR33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/0008-5472.CAN-19-0924","volume":"80","author":"M Yu","year":"2020","unstructured":"Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic aging: more than just a clock when it comes to cancer. Cancer Res. 2020;80:367\u201374.","journal-title":"Cancer Res"},{"key":"2240_CR34","volume":"20","author":"CG Bell","year":"2019","unstructured":"Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019;20:249.","journal-title":"Genome Biol"},{"key":"2240_CR35","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1038\/sj.onc.1206597","volume":"22","author":"M Udtha","year":"2003","unstructured":"Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms\u2019 tumors. Oncogene. 2003;22:3821\u20136.","journal-title":"Oncogene"},{"key":"2240_CR36","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.3390\/cancers13235888","volume":"13","author":"CC Yin","year":"2021","unstructured":"Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, et al. Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm. Cancers. 2021;13:5888.","journal-title":"Cancers"},{"key":"2240_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/gcc.22831","volume":"59","author":"AN Bastidas Torres","year":"2020","unstructured":"Bastidas Torres AN, Cats D, Mei H, Fanoni D, Gliozzo J, Corti L, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosom Cancer. 2020;59:295\u2013308.","journal-title":"Genes Chromosom Cancer"},{"key":"2240_CR38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2018.202093","volume":"104","author":"MR Sapienza","year":"2019","unstructured":"Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica. 2019;104:729\u201337.","journal-title":"Haematologica"},{"key":"2240_CR39","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","volume":"32","author":"K Sakamoto","year":"2018","unstructured":"Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018;32:2590\u2013603.","journal-title":"Leukemia"},{"key":"2240_CR40","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.3324\/haematol.2017.172742","volume":"102","author":"L Wang","year":"2017","unstructured":"Wang L, Yang M, Zhang X, Yang C, Huang X, Wang Z, et al. ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102:e470\u20132.","journal-title":"Haematologica"},{"key":"2240_CR41","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/leu.2017.101","volume":"31","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Suzuki Y, Hama A, Muramatsu H, Nakatochi M, Gunji M, et al. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017;31:1629\u201333.","journal-title":"Leukemia"},{"key":"2240_CR42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","volume":"28","author":"MR Sapienza","year":"2014","unstructured":"Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28:1606\u201316.","journal-title":"Leukemia"},{"key":"2240_CR43","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.celrep.2018.05.045","volume":"23","author":"F Bormann","year":"2018","unstructured":"Bormann F, Rodriguez-Paredes M, Lasitschka F, Edelmann D, Musch T, Benner A, et al. Cell-of-Origin DNA methylation signatures are maintained during colorectal carcinogenesis. Cell Rep. 2018;23:3407\u201318.","journal-title":"Cell Rep"},{"key":"2240_CR44","doi-asserted-by":"crossref","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, et al. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022;36:1343\u201350.","DOI":"10.1038\/s41375-022-01538-9"},{"key":"2240_CR45","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood"},{"key":"2240_CR46","doi-asserted-by":"crossref","first-page":"e28430","DOI":"10.1371\/journal.pone.0028430","volume":"6","author":"X Cai","year":"2011","unstructured":"Cai X, Gaudet JJ, Mangan JK, Chen MJ, De Obaldia ME, Oo Z, et al. Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One. 2011;6:e28430.","journal-title":"PLoS One"},{"key":"2240_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3:35\u201343.","journal-title":"Cancer Discov"},{"key":"2240_CR48","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s43018-022-00370-5","volume":"3","author":"S Hetzel","year":"2022","unstructured":"Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022;3:768\u201382.","journal-title":"Nat Cancer"},{"key":"2240_CR49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","volume":"75","author":"SM McCormick","year":"2015","unstructured":"McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75:38\u201350.","journal-title":"Cytokine"},{"key":"2240_CR50","first-page":"158","volume":"13","author":"R Straining","year":"2022","unstructured":"Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pr Oncol. 2022;13:158\u201363.","journal-title":"J Adv Pr Oncol"},{"key":"2240_CR51","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/cancers11050695","volume":"11","author":"PP Aung","year":"2019","unstructured":"Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, et al. PD1\/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. Cancers. 2019;11:695.","journal-title":"Cancers"},{"key":"2240_CR52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13072-017-0123-7","volume":"10","author":"K Skvortsova","year":"2017","unstructured":"Skvortsova K, Zotenko E, Luu PL, Gould CM, Nair SS, Clark SJ, et al. Comprehensive evaluation of genome-wide 5-hydroxymethylcytosine profiling approaches in human DNA. Epigenetics Chromatin. 2017;10:16.","journal-title":"Epigenetics Chromatin"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02240-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02240-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02240-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:11:26Z","timestamp":1714990286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02240-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02240-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG serves as an advisor for Stemline Therapeutics. The other authors declare that they have no conflict of interest relevant to the current manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}